- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05923073
En studie av Guselkumab hos pediatriska deltagare med måttligt till allvarligt aktiv Crohns sjukdom (MACARONI-23)
En fas 3, multicenter, randomiserad, plattformsstudie av p19-hämning av IL-23-vägen för att etablera effekt vid pediatrisk Crohns sjukdom
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Study Contact
- Telefonnummer: 844-434-4210
- E-post: Participate-In-This-Study1@its.jnj.com
Studieorter
-
-
-
Nedlands, Australien, 6009
- Rekrytering
- Perth Children's Hospital
-
South Brisbane, Australien, 4101
- Rekrytering
- Mater Hospital Brisbane
-
Westmead, Australien, 2145
- Rekrytering
- The Children's Hospital at Westmead
-
-
-
-
-
Brussels, Belgien, 1090
- Rekrytering
- Universitair Ziekenhuis Brussel
-
Brussels, Belgien, 1200
- Rekrytering
- Cliniques Universitaires Saint Luc
-
Ghent, Belgien, 9000
- Rekrytering
- Universitair Ziekenhuis Gent
-
Leuven, Belgien, 3000
- Rekrytering
- UZ Leuven
-
-
-
-
-
Campinas, Brasilien, 13060-904
- Rekrytering
- Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
-
Curitiba, Brasilien, 80250-060
- Rekrytering
- Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
-
Goiânia, Brasilien, 74605-020
- Rekrytering
- Universidade Federal de Goias - Hospital das Clinicas da UFG
-
Porto Alegre, Brasilien, 90035-074
- Rekrytering
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre, Brasilien, 90035-007
- Rekrytering
- Hospital De Clinicas De Porto Alegre
-
Vitória, Brasilien, 29040-091
- Rekrytering
- Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
-
Votuporanga, Brasilien, 100000
- Rekrytering
- INTEGRAL Pesquisa e Ensino
-
-
-
-
-
Amiens, Frankrike, 80054
- Rekrytering
- CHU Amiens-Hopital Nord
-
Lille, Frankrike, 59037
- Rekrytering
- Hôpital Jeanne de FLANDRE, CHRU LILLE
-
Paris, Frankrike, 75019
- Rekrytering
- Hôpital Robert Debré
-
Paris, Frankrike, 75015
- Rekrytering
- Hôpital Necker - Enfants Malades
-
-
-
-
California
-
Los Angeles, California, Förenta staterna, 90048
- Rekrytering
- Cedars Sinai Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Förenta staterna, 06106
- Rekrytering
- Connecticut Children's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Rekrytering
- Emory University
-
Atlanta, Georgia, Förenta staterna, 30342
- Rekrytering
- Children's Center for Digestive Health Care
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202-5225
- Rekrytering
- Riley Hospital for Children
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Rekrytering
- Boston Childrens Hospital
-
-
New Jersey
-
Morristown, New Jersey, Förenta staterna, 07960
- Rekrytering
- Goryeb Children's Hospital
-
-
New York
-
New York, New York, Förenta staterna, 10029
- Rekrytering
- Icahn School of Medicine at Mount Sinai
-
New York, New York, Förenta staterna, 10032
- Rekrytering
- Columbia University Medical Center
-
New York, New York, Förenta staterna, 10021-5663
- Rekrytering
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
-
-
Ohio
-
Dayton, Ohio, Förenta staterna, 45404
- Rekrytering
- The Children's Medical Center of Dayton
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Rekrytering
- Children's Hospital of Philadelphia
-
-
Texas
-
Fort Worth, Texas, Förenta staterna, 76104
- Rekrytering
- Cook Childrens Medical Center
-
-
Vermont
-
Colchester, Vermont, Förenta staterna, 05446
- Rekrytering
- University of Vermont Medical Center
-
-
-
-
-
Beersheba, Israel, 84101
- Rekrytering
- Soroka University Medical Center
-
Be’er Ya‘aqov, Israel, 70300
- Rekrytering
- Shamir Medical Center Assaf Harofeh
-
Jerusalem, Israel, 9103102
- Rekrytering
- Shaare Zedek Medical Center
-
Jerusalem, Israel, 9124001
- Rekrytering
- Hadassah Medical Center
-
Petah Tikva, Israel, 4920235
- Rekrytering
- Schneider Children's Medical Center
-
Rehovot, Israel, 761001
- Rekrytering
- Kaplan Medical Center
-
-
-
-
-
Alessandria, Italien, 15121
- Rekrytering
- A.O. Santi Antonio e Biagio e Cesare Arrigo
-
Bergamo, Italien, 24127
- Rekrytering
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
Bologna, Italien, 40124
- Rekrytering
- Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
-
Florence, Italien, 50139
- Rekrytering
- Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
-
Milan, Italien, 20154
- Rekrytering
- Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
-
Roma, Italien, 161
- Rekrytering
- AOU Policlinico Umberto I
-
-
-
-
-
Hirosaki, Japan, 036-8563
- Rekrytering
- Hirosaki University Hospital
-
Kagoshima, Japan, 890-8544
- Rekrytering
- Kagoshima University Hospital
-
Kashiwa-shi, Japan, 277-0871
- Rekrytering
- Tsujinaka Hospital Kashiwanoha
-
Kobe, Japan, 650 0017
- Rekrytering
- Kobe University Hospital
-
Saga, Japan, 849-8501
- Rekrytering
- Saga University Hospital
-
Sendai, Japan, 989-3126
- Rekrytering
- Miyagi Childrens Hospital
-
Setagaya Ku, Japan, 157 8535
- Rekrytering
- National Center for Child Health and Development
-
Tokyo, Japan, 113-8431
- Rekrytering
- Juntendo University Hospital
-
Tsu, Japan, 514 8507
- Rekrytering
- Mie University Hospital
-
Ube, Japan, 755-8505
- Rekrytering
- Yamaguchi University Hospital
-
Yokohama, Japan, 232-0024
- Rekrytering
- Yokohama City University Medical Center
-
Yokohama, Japan, 230-8765
- Rekrytering
- Saiseikai Yokohamashi Tobu Hospital
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- Rekrytering
- Iwk Health Centre
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9
- Rekrytering
- London Health Sciences Centre Victoria Hospital
-
Toronto, Ontario, Kanada, M5G 1X8
- Rekrytering
- Hospital For Sick Children
-
-
-
-
-
Rotterdam, Nederländerna, 3015 GD
- Rekrytering
- Erasmus Medisch Centrum
-
-
-
-
-
Nordbyhagen, Norge, 1474
- Rekrytering
- Akershus Universitetssykehus HF
-
Oslo, Norge, 424
- Rekrytering
- Oslo University Hospital
-
Tromsø, Norge, 9038
- Rekrytering
- Universitetssykehuset Nord-Norge HF
-
Trondheim, Norge, 7030
- Rekrytering
- St. Olavs Hospital
-
-
-
-
-
Rzeszów, Polen, 35-302
- Rekrytering
- Korczowski Bartosz Gabinet Lekarski
-
Warsaw, Polen, 04 501
- Rekrytering
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw, Polen, 04 730
- Rekrytering
- Instytut Pomnik Centrum Zdrowia
-
-
-
-
-
Braga, Portugal, 4710-243
- Rekrytering
- Hospital de Braga
-
Lisbon, Portugal, 1649-035
- Rekrytering
- Centro Hospitalar de Lisboa Norte Hospital Santa Maria
-
Porto, Portugal, 4200-319
- Rekrytering
- Centro Hospitalar de Sao Joao E.P.E.
-
-
-
-
-
Córdoba, Spanien, 14004
- Rekrytering
- Hosp Reina Sofia
-
Sabadell, Spanien, 8208
- Rekrytering
- Corporacio Sanitari Parc Tauli
-
Valencia, Spanien, 46026
- Rekrytering
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Glasgow, Storbritannien, G51 4TF
- Rekrytering
- Royal Hospital for Sick Children
-
London, Storbritannien, WC1N 3JH
- Rekrytering
- Great Ormond Street Hospital
-
Manchester, Storbritannien, M13 9WL
- Rekrytering
- Royal Manchester Children's Hospital
-
Manchester, Storbritannien, M13 9WL
- Rekrytering
- Nowgen Centre, Research and Innovation
-
Oxford, Storbritannien, OX3 9DU
- Rekrytering
- John Radcliffe Hospital
-
Sheffield, Storbritannien, S10 2TH
- Rekrytering
- Sheffield Children's Hospital
-
-
-
-
-
Busan, Sydkorea, 48108
- Rekrytering
- Inje University Haeundae Paik Hospital
-
Daegu, Sydkorea, 41404
- Rekrytering
- Kyungpook National University Chilgok Hospital
-
Seoul, Sydkorea, 03080
- Rekrytering
- Seoul National University Hospital
-
Seoul, Sydkorea, 06351
- Rekrytering
- Samsung Medical Center
-
Seoul, Sydkorea, 120-752
- Rekrytering
- Severance Hospital Yonsei University Health System
-
-
-
-
-
Vienna, Österrike, 1090
- Rekrytering
- AKH - Medizinische Universitat Wien
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
- Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
- Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
- Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)
Exclusion Criteria:
- Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
- Participants must not have an abscess
- Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Open-label induction phase: Guselkumab Intravenously (IV)
Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
Andra namn:
Guselkumab will be administered intravenously.
Andra namn:
|
|
Experimentell: Open-label induction phase: Guselkumab Subcutaneously (SC)
Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
Andra namn:
Guselkumab will be administered intravenously.
Andra namn:
|
|
Experimentell: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Andra namn:
Guselkumab will be administered intravenously.
Andra namn:
|
|
Experimentell: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Andra namn:
Guselkumab will be administered intravenously.
Andra namn:
|
|
Experimentell: Open-label maintenance phase: Guselkumab SC
Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Andra namn:
Guselkumab will be administered intravenously.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Participants with Clinical Remission at Week 52
Tidsram: Week 52
|
Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Tidsram: Week 52
|
Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline. |
Week 52
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Participants with Clinical Response at Week 12
Tidsram: Week 12
|
Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 12
|
|
Percentage of Participants with Clinical Response at Week 52
Tidsram: Week 52
|
Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 52
|
|
Percentage of Participants with Clinical Remission at Week 12
Tidsram: Week 12
|
Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 12
|
|
Percentage of Participants with Endoscopic Remission at Week 52
Tidsram: Week 52
|
Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1. |
Week 52
|
|
Percentage of Participants with Corticosteroid-free Remission at Week 52
Tidsram: Week 52
|
Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52. |
Week 52
|
|
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
Tidsram: Weeks 12, 24, and 52
|
Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52. |
Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
Tidsram: Week 12 and/or Week 52
|
Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline. |
Week 12 and/or Week 52
|
|
Serum Concentration of Guselkumab During Induction Phase
Tidsram: From Week 0 to Week 12
|
Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method. |
From Week 0 to Week 12
|
|
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
Tidsram: At Weeks 16, 24, 36, 48 and 52
|
Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration. |
At Weeks 16, 24, 36, 48 and 52
|
|
Change from Baseline in Body Weight at Weeks 12, 24, and 52
Tidsram: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
Tidsram: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
Tidsram: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height at Weeks 12, 24, and 52
Tidsram: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
Tidsram: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
Tidsram: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
Tidsram: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical Remission
Tidsram: Week 52
|
Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response
Tidsram: Week 52
|
Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline. |
Week 52
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: Up to Week 64
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important. |
Up to Week 64
|
Samarbetspartners och utredare
Utredare
- Studierektor: Clinical Trial, Janssen Research & Development, LLC
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CR109212
- 2021-006282-37 (EudraCT-nummer)
- CNTO1959PBCRD3007 (Annan identifierare: Janssen Research & Development, LLC)
- 2023-504735-41-00 (Registeridentifierare: EUCT number)
- 2023 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .